

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**Current Report  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):  
June 25, 2025**

---

**Definitive Healthcare Corp.**

(Exact name of Registrant as Specified in Its Charter)

---

**Commission File Number 001-40815**

**Delaware**  
(State of Incorporation)

**86-3988281**  
(IRS Employer Identification No.)

**492 Old Connecticut Path, Suite 401  
Framingham, Massachusetts 01701**  
(Address of Principal Executive Offices)

**(508) 720-4224**  
Registrant's telephone number, including area code

**Not Applicable**  
(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<small>Title of Each Class</small>	<small>Trading Symbol</small>	<small>Name of Each Exchange on Which Registered</small>
<b>Class A Common Stock, \$0.001 par value</b>	<b>DH</b>	<b>The Nasdaq Stock Market LLC</b>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On June 25, 2025, as part of its planning and organizational design with respect to its executive leadership team, Definitive Healthcare Corp. (the “Company”) agreed with Kate Shamsuddin Jensen that the Chief Operating Officer position that she held would be eliminated. Accordingly, Ms. Shamsuddin Jensen will remain employed with the Company through August 1, 2025. Ms. Shamsuddin Jensen’s departure constitutes a termination of employment without “cause” for purposes of any employment, equity compensation, or benefit agreement, plan, or arrangement of the Company and its subsidiaries to which Ms. Shamsuddin Jensen is a party or in which she otherwise participates.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**DEFINITIVE HEALTHCARE CORP.**

July 1, 2025

Date

By: /s/ Casey Heller

Name: Casey Heller

Title: Chief Financial Officer

---

